Author

Igor Smolenov

Arcturus Therapeutics - Cited by 2,986 - Public Health - Clinical development - Vaccines - Infectious diseases

Biography

Dr.Igor Smolenov, Cluster Head, Novartis Vaccines, as a cluster head, I am responsible for global clinical development activities and related regulatory strategies for several vaccine programs. In this role, I lead a multidisciplinary team in the Netherlands, USA,Twelve years of increasingly responsible experience and leadership in clinical development. Contribute to successful development and licensure of several innovative vaccines.
Title
Cited by
Year
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
RA Feldman, R Fuhr, I Smolenov, AM Ribeiro, L Panther, M Watson, ...Vaccine 37 (25), 3326-3334, 2019201
343
2019
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
P Richmond, L Hatchuel, M Dong, B Ma, B Hu, I Smolenov, P Li, P Liang, ...The lancet 397 (10275), 682-694, 2021202
229
2021
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
AO Aliprantis, CA Shaw, P Griffin, N Farinola, RA Railkar, X Cao, W Liu, ...Human vaccines & immunotherapeutics 17 (5), 1248-1261, 2021202
71
2021
A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial
SL Block, L Szenborn, W Daly, T Jackowska, D D’Agostino, L Han, ...Vaccine 33 (21), 2500-2510, 2015201
59
2015
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
L Bravo, I Smolenov, HH Han, P Li, R Hosain, F Rockhold, SAC Clemens, ...The Lancet 399 (10323), 461-472, 2022202
56
2022
Факторы, влияющие на качество жизни больных с бронхиальной астмой
АГ Чучалин, АС Белевский, ИВ Смоленов, НА Смирнов, ЯГ АлексееваПульмонология, 67-83, 2021202
52
2021
Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants
R Baxter, P Keshavan, JA Welsch, L Han, I SmolenovHuman Vaccines & Immunotherapeutics 12 (5), 1300-1310, 2016201
38
2016
Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults
B Essink, C Fierro, J Rosen, AL Figueroa, B Zhang, C Verhoeven, ...Vaccine 38 (2), 242-250, 2020202
33
2020
Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration
R Gasparini, M Tregnaghi, P Keshavan, E Ypma, L Han, I SmolenovThe Pediatric Infectious Disease Journal 35 (1), 81-93, 2016201
32
2016
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 …
J Beran, H Reynales, A Poder, YY Charles, P Pitisuttithum, LL Yuan, ...The Lancet Infectious Diseases 21 (7), 1027-1037, 2021202
31
2021
Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents
X Saez-Llorens, DC Aguilera Vaca, K Abarca, E Maho, MG Graña, ...Human vaccines & immunotherapeutics 11 (6), 1507-1517, 2015201
30
2015
Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents …
JA Welsch, S Senders, B Essink, T Klein, I Smolenov, P Pedotti, S Barbi, ...Vaccine 36 (35), 5309-5317, 2018201
26
2018
Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers
G Bona, P Castiglia, G Zoppi, M de Martino, A Tasciotti, D D’Agostino, ...Vaccine 34 (29), 3363-3370, 2016201
23
2016
Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination
SL Block, S Christensen, B Verma, F Xie, P Keshavan, PM Dull, ...Vaccine 33 (18), 2175-2182, 2015201
22
2015
Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial
C Shaw, L Panther, A August, T Zaks, I Smolenov, S Bart, M WatsonInternational Journal of Infectious Diseases 79, 17, 2019201
22
2019
Immunogenicity and Safety of a 3-and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants
SL Block, J Shepard, H Garfield, F Xie, L Han, PM Dull, I SmolenovThe Pediatric infectious disease journal 35 (2), e48-e59, 2016201
21
2016
Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents
X Saez-Llorens, DCA Vaca, K Abarca, E Maho, L Han, I Smolenov, P DullThe Pediatric Infectious Disease Journal 34 (10), e264-e278, 151
20
2015
Comparative assessment of a single dose and a 2-dose vaccination series of a quadrivalent meningococcal CRM-conjugate vaccine (MenACWY-CRM) in children 2–10 years of age
W Johnston, B Essink, J Kirstein, E Forleo-Neto, S Percell, L Han, ...The Pediatric infectious disease journal 35 (1), e-e27, 2016201
19
2016
Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines
L Szenborn, SL Block, T Jackowska, R Konior, D D’Agostino, I Smolenov, ...The Pediatric Infectious Disease Journal 37 (5), 475-482, 2018201
17
2018
Meningococcal serogroup ACWYX conjugate vaccine in Malian toddlers
MD Tapia, SO Sow, A Naficy, F Diallo, FC Haidara, A Chaudhari, ...New England Journal of Medicine 384 (22), 2115-2123, 2021202
16
2021

Referred From: https://scholar.google.com/citations?user=VXImvBsAAAAJ&hl=ru

Cited by
Citations 2986
h-index 28
i10-index 68
Recommended Journals
Open Access Journals